Abstract. The aim of the present study was to investigate the effect of realgar on the viability, proliferation and apoptosis in the human chronic lymphocytic leukemia (CLL) cell line, MEC-1. Potential mechanisms mediating the effect were also explored in the experiment. Cultured MEC-1 cells were incubated with various concentrations of realgar for 24, 48 and 72 h. A WST-8 assay was employed to evaluate the effect on cell viability. Inhibitory effects on cell proliferation were determined using a 5-bromodeoxyuridine cell proliferation ELISA. The apoptotic effect on MEC-1 cells was evaluated by annexin V-fluorescein isothiocyanate/propidium iodide dual staining, followed by flow cytometry. Quantitative polymerase chain reaction was performed to determine the mRNA expression levels of BCL2-associated X protein (BAX), BCL2-like 1 (Bcl-xL), v-myc myelocytomatosis viral oncogene homolog (avian; c-Myc) and cyclin-dependent kinase inhibitor 1A (p21). It was found that viability and proliferation were significantly reduced while apoptotic rates increased in MEC-1 cells following exposure to realgar. Furthermore, mRNA expression of BAX and c-Myc was upregulated and downregulated, respectively, in realgar-treated MEC-1 cells. In conclusion, the results showed that realgar inhibits viability and proliferation and induces apoptosis of MEC-1 cells in a dose-and time-dependent manner. The effect may depend on the mitochondrial apoptosis pathway. The results of the present study may be beneficial in the identification of a new target therapy for CLL.
Introduction
Traditional Chinese medicine (TCM) has been used as effective antitumor agents for numerous years in ancient China (1) . However, it is difficult to identify the active ingredient due to the complex composition. Thus, the use of TCM has been severely restricted in clinical practices following the introduction of western antineoplastic methods, including radiotherapy and chemotherapy. The therapeutic efficacy of arsenic trioxide (As 2 O 3 ) has been shown previously in the treatment of acute promyelocytic leukemia (APL), of which the mechanism has also been identified (2) (3) (4) (5) (6) . Consequently, TCM has become an important area of study again and attracted considerable attention in aspects of cancer treatment, particularly in the treatment of malignant hematologic diseases. Numerous studies have been conducted thus far, yielding a number of achievements (7) (8) (9) (10) (11) .
As 2 O 3 and realgar (arsenic sulfide, As 2 S 2 ) belong to a group of Chinese arsenic drugs (12) and have a number of similarities. For example, realgar and As 2 O 3 exhibit a good antitumor effect. Realgar is the principal constituent in the Realgar-Indigo naturalis formula (RIF), together with Indigo naturalis, Salvia miltiorrhiza and Radix Pseudostellariae. RIF shows satisfactory efficacy in treating human APL (13) . Realgar has also been shown to induce apoptosis of chronic myelogenous leukemia (CML) cells through the degradation of BCR-ABL (14, 15) . Results of recent studies have shown that As 2 O 3 induced apoptosis of chronic lymphocytic leukemia (CLL) cells (16, 17) . This effect on CLL cells may be mediated by suppressing the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH 2 terminal kinase activation and PTEN upregulation (17) . However, whether realgar induces apoptosis of CLL cells remains unknown.
CLL is the most common adult leukemia in western countries. It is a highly heterogeneous disease. Immunoglobulin heavy chain variable mutation status, cytogenetic changes and expression of CD38 and ZAP-70 differ among patients. Although the survival rate of CLL has improved over the past decade, with the exception of allogeneic bone marrow transplantation, no treatment is sufficiently effective to completely cure the disease. Particularly for CLL with a 17p deletion, it is almost impossible to avoid deterioration. Therefore, the purpose of the present study was to investigate the effect of realgar on the viability, proliferation and apoptosis of the human p53 deleted/mutated CLL cell line, MEC-1. In addition, the potential mechanism mediating the effect were explored during the study.
Materials and methods

Cell lines. Human p53
deleted/mutated CLL cell line, MEC-1, was suspended in Iscove's modified Dulbecco's medium (IMDM; HyClone Laboratories, Inc., Logan, UT, USA) containing 10% fetal bovine serum (HyClone), 100 U/ml penicillin and 100 µg/ml streptomycin. Culturing conditions were maintained at 37˚C in a humidified atmosphere containing 5% CO 2 .
Reagents. Realgar (purity, 99.53%) was purchased from Alfa Aesar (Ward Hill, MA, USA). It was dissolved in 0.1 M sodium hydroxide and the pH was adjusted to 7.35-7.45 using hydrochloric acid (14, 18) . The stock solution (1 mM As 2 S 2 ) was then passed through a 0.22 µm filter. IMDM was used to dilute the solution prior to cell application. 
5-Bromodeoxyuridine (BrdU) cell proliferation assay.
A BrdU cell proliferation ELISA kit (Roche Diagnostics Co., Indianapolis, IN, USA) was used to evaluate the inhibitory effects of realgar on cell proliferation, according to the manufacturer's instructions. MEC-1 cells with a density of 1x10 4 cells/ml were exposed to various concentrations (0, 2, 6 and 10 µM) of realgar for 24 and 48 h. BrdU (10 µl/well) was then added. Following incubation for an additional 2 h, the culture medium was removed and the cells were fixed. Following incubation with the antiBrdU-peroxidase for 1 h and the substrate reaction, 25 µl of 1 M H 2 SO 4 was applied and the absorbance was read on an ELISA reader at 450 nm. 
Gene expression study by quantitative polymerase chain reaction (PCR).
Transcriptional levels of BCL2-associated X protein (BAX), BCL2-like 1 (Bcl-xL), v-myc myelocytomatosis viral oncogene homolog (avian; c-Myc) and cyclin-dependent kinase inhibitor 1A (p21) genes, in realgar-treated and untreated MEC-1 cells, were evaluated by quantitative PCR. Total RNA was extracted by TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) from MEC-1 cells following incubation with 0 and 6 µM realgar for 48 h. Reverse transcription to complementary DNA (cDNA) was performed using PrimeScript RT reagent kit with gDNA eraser (Takara Biotechnology Co., Ltd., Dalian, China). Quantitative PCR for the aforementioned genes was performed using a SYBR Premix Ex Taq II (Tli RNase H Plus) kit (Takara Biotechnology Co., Ltd.) on a Roche LightCycler 480 (Roche Diagnostics Co.). Actin was used as an internal control. The sequences of the quantitative PCR primers are listed in Table I . Isolation of RNA, reverse transcription and quantitative PCR were performed following the manufacturer's instructions. For data analysis the 2 -ΔΔCt method was used with the following equations: ΔCt = Ct (target gene) -Ct (actin); ΔΔCt = ΔCt (realgar-treated cells) -ΔCt (untreated control). Quantitative PCR for each gene of each cDNA sample was assayed in triplicate.
Statistical analysis. Statistical analysis was performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as mean ± SD. The significance of differences between groups was determined using the Student's t-test or ANOVA. P<0.05 was considered to indicate a statistically significant difference. 
Results
Realgar
Realgar induces apoptosis of MEC-1 cells.
The apoptotic effect of realgar on MEC-1 cells was determined by annexin V-FITC/PI dual staining, followed by flow cytometry analysis. As shown in Fig. 3 , apoptosis of MEC-1 cells was induced by realgar in a dose-and time-dependent manner. Following treatment with 2 µM realgar for 24 h, the percentage of apoptotic cells increased between 6.78±0.60 and 9.26±1.25% (P<0.05). With an increase in incubation time or concentration of realgar, the induction of apoptosis was significantly enhanced. Percentages of apoptotic cells, following incubation with 2 µM realgar for 48 h and 6 µM for 24 h, were 14.44±1.54 (P<0.01) and 36.09±2.48% (P<0.01), respectively.
Realgar upregulates mRNA levels of BAX while downregulating mRNA levels of c-Myc. To further investigate whether realgar-induced apoptosis was dependent on the mitochondrial apoptosis pathway, the effect of realgar on the mRNA levels of BAX, Bcl-xL, c-Myc and p21 genes was measured by quantitative PCR. Following treatment with 6 µM realgar for 48 h, mRNA expression of BAX in MEC-1 cells was upregulated almost 2-fold while c-Myc mRNA expression was reduced by more than half (Fig. 4) . However, no significant difference in the expression of Bcl-xL and p21 was observed between the realgar-treated and untreated MEC-1 cells.
Discussion
Studies have been conducted on the antineoplastic effect of realgar. Realgar has been shown to have antiproliferative and pro-apoptotic effects on a number of cancer cell lines, including rat glioma C6 cells, mouse melanoma B16 cells and the cervical cancer cell line SiHa (19) (20) (21) . More studies on the antineoplastic effect of realgar have been carried out in a few cells types of malignant hematologic diseases. The majority of these studies have focused on promyelocytic leukemia HL-60 cells, APL cell line NB4 and CML cell line K562, as well as peripheral blood or bone marrow cells gained from APL and CML patients. Consequently, considerable success has been achieved. Oxidative stress, membrane toxicity and protein tyrosine kinase may be involved in the process of realgar-induced apoptosis (14, 22) . Realgar has been reported to induce apoptosis in human histocytic lymphoma U937 cells through caspase, MAPK and mitochondrial pathways (23, 24) . However, no studies focusing on the effect of realgar on CLL cells have been conducted prior to this study.
CLL is a malignant disease of B lymphocytes, initially recognized as the result of accumulation of rest cells. However, CLL was later found to be a disease of activated monoclonal cells that proliferated in particular microenvironments (25, 26) . The molecular mechanism leading to the imbalance between apoptosis and proliferation has attracted considerable attention and associated pathways have been explored widely in order to identify new therapies targeted to cure CLL. In the present study, arsenic compound realgar was used to dispose MEC-1 cells. The MEC-1 cell line was established from the peripheral blood of a CLL patient in prolymphocytoid transformation (27) . Several cytogenetic aberrations were detected, including del(17)(p11.2pter) (27) . It was found that realgar, not only suppressed viability and proliferation, but also induced apoptosis of MEC-1 cells.
Further investigations were performed analyzing the effect various doses and incubation times had on MEC-1 cells. Following exposure to various concentrations of realgar for different time periods, cell viability and proliferation were inhibited in MEC-1 cells in a dose-and time-dependent manner. The effect of realgar on apoptosis was also evaluated in MEC-1 cells and found to induce apoptosis in a dose-and time-dependent manner. Potential mechanisms involved in the realgar-induced apoptosis were explored. mRNA expression of BAX and c-Myc was upregulated and downregulated, respectively, following realgar treatment. BAX belongs to the Bcl-2 family of pro-apoptotic genes and is an important member of the mitochondrial apoptosis pathway (28) . Protein encoded by the c-Myc gene functions as a transcription factor that participates in significant processes, including cell cycle progression, apoptosis and cell transformation. Changes in mRNA expression levels of BAX and c-Myc indicated that realgar-induced apoptosis of MEC-1 cells may be dependent on the mitochondrial pathway.
In summary, the inhibitory effect of realgar on the CLL cell line, to the best of our knowledge, was explored for the first time. Based on the findings of the present study, it may be concluded that realgar inhibited viability and proliferation and induced apoptosis of MEC-1 cells in a dose-and time-dependent manner. This phenomenon may depend on the mitochondrial apoptosis pathway, as the upregulation of BAX expression and downregulation of c-Myc expression was observed in MEC-1 cells following realgar treatment. The results of the present study may be beneficial for the identification of a new target therapy for CLL. In addition, more studies are required to explore the detailed mechanism involved in the process.
